doi: 10.1038/s41598-023-42760-4, 18 ChenL.MinJ.WangF
Lipton, MD, Professor of Neurology and Director of the Montefiore Headache Center, Albert Einstein College of Medicine, commented, A significant proportion of migraine patients experience inadequate efficacy with currently available acute treatments, leading to even greater suffering, and an increased risk of worsening of migraine pain and attack frequency
particularly low-volume rural and small hospitals may be unable to report on many of the included measures
North America dominated the market with revenue of USD 1.2 billion in 2025, and is projected to grow at a CAGR of 19.8% through 2034, owing to the presence of a high number of obese and diabetic patients, along with well-developed insurance facilities that promote development of advanced metabolic treatments and regulatory frameworks that make it easier to obtain approval for hormonal combination therapies